pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Examining the structure and function of the cornea at the molecular level, Investigating corneal cell biology, and Translational research initiatives dedicated to improving laser refractive surgery techniques that can help address certain complications that can arise following these procedures. Hafezi is considered to be a leading expert and key opinion leader in the development and translation of CXL and its multiple applications in the field of ophthalmology, including the treatment of corneal ectatic disorders like keratoconus, pellucid marginal degeneration and post-LASIK ectasia. Hafezi and his colleagues have also pioneered the use of CXL for the treatment of corneal infections, calling the technique "photoactivated chromophore for infectious keratitis cross-linking", or PACK-CXL. Hafezi has published almost 200 articles in various peer-reviewed scientific journals since 1993, including Nature Medicine, Nature Genetics, Investigative Ophthalmology & Visual Science (IOVS), the Journal of Refractive Surgery, and Cell Death & Differentiation. His work in the field of corneal collagen cross-linking has led him to receive a number of international awards. In 2014, 2016, 2018, 2020, 2023, 2025, and 2026 his peers ranked Hafezi as one of the top 100 most influential people in ophthalmology.
== Composition == The substance is primarily composed of polysaccharides, including galactose, rhamnose, and α-glucuronic acid. It also contains dietary fiber, carbohydrates, proteins, and small amounts of vitamins. Despite marketing claims, peach gum does not contain collagen, which is exclusive to animal tissues.
Ravenholm is a fictional ghost town in the 2004 first-person shooter game Half-Life 2 created by Valve. It is the setting for the game's sixth chapter, "We Don't Go To Ravenholm...", which follows protagonist Gordon Freeman as he journeys through the area after escaping a Combine attack in order to reach a nearby Resistance outpost. An Eastern European mining town, Ravenholm's residents have turned into hostile zombies due to Combine attacks. The town's sole survivor, Father Grigori, offers his assistance to Freeman throughout the level, culminating in a last stand at the town cemetery. The level received critical praise due to its level design and unexpected usage of horror aspects involving headcrabs and zombies, with some critics calling it one of the most well-designed levels in a Valve game and one of the best first-person shooter levels ever made. Due to its popularity, Valve initially contracted Junction Point Studios to make a prequel featuring the town, a project that later became a spinoff game developed by Arkane Studios that further followed the story of Grigori and his fight against the Combine. However, both projects were ultimately cancelled partway through development.
Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca. The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite. Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca.
=== Naval warfare capabilities === In course of the Yemeni Civil War, the Houthis developed tactics to combat their opponents' navies. At first, their anti-ship operations were unsophisticated and limited to rocket-propelled grenades being shot at vessels close to the shore. In the fight to secure the port city of Aden in 2015, the Yemeni Navy was largely destroyed, including all missile-carrying vessels. A number of smaller patrol craft, landing craft, and Mi-14 and Ka-28 ASW helicopters did survive. Their existence under Houthi control would be brief, as the majority of them were destroyed in air attacks during the Saudi-led intervention in Yemen in 2015. As a result, the Houthis were left with AShMs (anti-ship missiles) stored ashore, but no launchers, and a smattering of small patrol ships. These, along with a number of locally manufactured small craft and miscellaneous vessels, were to form the foundation of the new naval warfare capabilities. Soon after the Houthis took over Yemen in 2015, Iran sought to strengthen the Houthis' naval capabilities, allowing the Houthis, and thus Iran, to intercept Coalition shipping off the Red Sea coast, by providing additional AShMs and constructing truck-based launchers that could easily be hidden after a launch. Iran also anchored the MV Saviz intelligence vessel, disguised as a regular cargo vessel, off the coast of Eritrea, that provided intelligence and updates on Coalition ship movements to the Houthis.
Sources: en.wikipedia.org
Laboratory Test Request and Sample Receiving Test Preparation, LIMS Processing, Test Results Recording and Verification Report Preparation and Distribution Laboratory Test Scheduling Prescheduled Testing Specimen and Sample Tracking/Chain of Custody Media, Reagents, Controls: Manufacturing and Inventory Interoperability and Data Exchange Statistical Analysis and Surveillance Billing for Laboratory Services Contract and Grant Management Training, Education and Resource Management Laboratory Certifications/Licensing Customer Relationship Management Quality Control (QC) and Quality Assurance (QA) Management Laboratory Safety and Accident Investigation Laboratory Mutual Assistance/Disaster Recovery Core IT Service Management: Hardware, Software and Services Policies and Procedures, including Budgeting and Funding
=== Clinical trials === Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). Retatrutide is also being evaluated in phase 3 clinical trials. Two trials in the phase 3 TRIUMPH program reached primary completion in April 2026: TRIUMPH-1, a master protocol in adults with obesity or overweight, and TRIUMPH-3, in participants with severe obesity and established cardiovascular disease. A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks. Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors. Reports on its development state that it was engineered for activity across these targets. Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations. Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials. Safety assessments also indicate a low risk of hypoglycemia and no significant elevation in cardiovascular or hepatic adverse events in non-diabetic populations across published studies.
Oxycodone is the most widely recreationally used opioid in America. In the United States, more than 12 million people use opioid drugs recreationally. The U.S. Department of Health and Human Services estimates that about 11 million people in the U.S. consume oxycodone in a non-medical way annually. Opioids were responsible for 49,000 of the 72,000 drug overdose deaths in the U.S. in 2017. In 2007, about 42,800 emergency room visits occurred due to "episodes" involving oxycodone. In 2008, recreational use of oxycodone and hydrocodone was involved in 14,800 deaths. Some of the cases were due to overdoses of the acetaminophen component, resulting in fatal liver damage. In September 2013, the US Food and Drug Administration (FDA) released updated labeling guidelines for long-acting and extended-release opioids requiring manufacturers to remove moderate pain as an indication for use, instead stating the drug is for "pain severe enough to require daily, around-the-clock, long term opioid treatment". The updated labeling does not restrict physicians from prescribing opioids for moderate pain, as needed. Reformulated OxyContin is causing some recreational users to change to heroin, which is cheaper and easier to obtain.
=== Ethiopia === Ethiopia is experiencing a severe fuel crisis, with over 180,000 tonnes of fuel undelivered in recent weeks. This has halved the country's daily diesel supply from 9.2 million to 4.5 million litres, according to Minister Kassahun Gofe. In Ethiopia, security institutions have been prioritised, along with, major government projects, key industries, and essential goods production. There are fuel restrictions, and petrol stations are prioritising public transport. Fuel supplies to the Tigray Region have been completely suspended. Addis Ababa residents have reported that, “Over the past month, prices of many commodities have increased significantly ...bottled water, cooking oil, eggs and other essentials have risen by nearly 40 per cent.”
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.